Paragon Genomics, Inc.
Hayward
About Paragon Genomics, Inc.
At Paragon Genomics, we develop and commercialize rapid, easy-to-use, ultra-high multiplex PCR-based target enrichment solutions for Next-Generation Sequencing (NGS). Our proprietary CleanPlex® background-removing technology enables NGS customers to develop targeted sequencing assays that are accurate, sensitive, and simple, yet cost effective. Our technology is applicable to many fast-growing NGS segments such as cancer research, liquid biopsy, biomarker discovery, genomics-guided breeding, companion diagnostics, and immunotherapy monitoring.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2017)
- Website: paragongenomics.com
- Phone: 510-363-9918
Industries & Categories
Biotechnology, Emergency Medicine, Health Care, Information Technology, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/paragon-genomics-inc-94977 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.